Clinical trials: Cardiomyopathy Ischemic
Ventricular Tachycardia, Ischemic Cardiomyopathy
Ablation at Virtual-hEart pRedicted Targets for VT
The goal of this study is to test the efficacy of the new imaging/simulation ("virtual heart") approach for determining the optimal ablation sites in patients with VT, which render post-infarction VT non-inducible.
- Trial name
- AVERT-VT (NCT03536052)
- Testing
- Virtual Heart Guided Ablation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Ischemic and Non-ischemic Cardiomyopathy
OptiVol for Precision Medical Management of Heart Failure
This clinical study is designed to show that a multidisciplinary team following a pre-specified standard of care medication decision model based on data from an implanted cardioverter device will increase the rate of change in…
- Trial name
- (OPTIMED-HF) (NCT04206501)
- Testing
- Medtronic ICD with Opti Vol-Monitor
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Rochester
Heart Failure, Ischemic Cardiomyopathy
Scar Location and Acute Haemodynamic Response to MultiPoint Pacing Study in Patients With Ischemic Cardiomyopathy
Cardiac Resynchronization Therapy (CRT) is a proven treatment for heart failure. CRT consists of a special pacemaker with two/three leads (insulated wires which take the electrical impulses from the device to the heart), one in…
- Trial name
- NCT04066738
- Testing
- Cardiac MRI with gadolinium contrast, 3D reconstruction and location of coronary sinus venous system relative to myocardial scar, Acute haemodynamic measurements during CRT implant
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- Oxford University Hospitals NHS Trust
Ischemic Heart Disease, Non-ischemic Cardiomyopathy
Serial Infusions of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients With Left Ventricular Assist Device
A study to assess the safety and preliminary efficacy of serial intravenous dose of Allogeneic Mesenchymal Bone Marrow Cells in subjects with heart failure and implanted left ventricular assist devices.
- Trial name
- STEM-VAD (NCT03925324)
- Testing
- Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Medstar Health Research Institute
Congestive Heart Failure, Ischemic Cardiomyopathy
Feasibility and Effectiveness of Micronutrients as Palliative Care Therapy in Patients With Congestive Heart Failure
The purpose of this project is to conduct a preliminary test of the feasibility of a multi-micronutrient intervention to improve micronutrient status, cardiac function and quality of life in Veterans with Congestive Heart Failure…
- Trial name
- NCT01474486
- Testing
- Micronutrients
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Phoenix VA Health Care System
Ischemic Cardiomyopathy
Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure
This is a phase II, randomized, placebo-controlled clinical trial designed to assess feasibility, safety, and effect of autologous bone marrow-derived mesenchymal stem cells (MSCs) and c-kit+ cells both alone and in combination…
- Trial name
- CONCERT-HF (NCT02501811)
- Testing
- Mesenchymal Stem Cells (MSC), c-kit+ cells
- Where
- 7 sites in United States
- Volunteers
- 125 people
- Sponsor
- The University of Texas Health Science Center, Houston
Hypertrophic Cardiomyopathy, Non-ischemic Dilated Cardiomyopathy
Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve
The aim of this study is to assess microvascular function as determined by a cardiovascular magnetic resonance measurement of whole-heart (global) perfusion reserve.
- Conditions
- Hypertrophic Cardiomyopathy, Non-ischemic Dilated Cardiomyopathy, Microvascular Ischaemia of Myocardium
- Trial name
- NCT03249272
- Testing
- Regadenoson, Adenosine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Duke University
ISCHEMIC CARDIOMYOPATHY
Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury
The purpose of this study is to evaluate the safety and tolerance of a new intravenous diagnostic agent, SeeMore or EVP 1001-1, in patients with Cardiovascular Disease (MEMRI scan).
- Trial name
- NCT02933034
- Testing
- Manganese-enhanced MRI contrast reagent, Gadolinium-enhanced MRI contrast reagent
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Stanford University
Ventricular Tachycardia, Ischemic Cardiomyopathy
Contrast ICE for Myocardial Scar in VT Ablations
There is a high correlation between scar areas identified by contrast-enhanced ICE and scar areas identified by conventional electroanatomic mapping.
- Trial name
- NCT03212326
- Testing
- Perflutren Lipid Microsphere Intravenous Suspension [DEFINITY]
- Volunteers
- 24 people
- Sponsor
- Weill Medical College of Cornell University
Non-left Bundle Branch Block, Ischemic or Non-ischemic Cardiomyopathy
CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients
The purpose of this study is to analyze the effect of left ventricular lead pacing location in the non-left bundle branch block (non-LBBB) heart failure patient population.
- Trial name
- ENHANCE CRT (NCT01983293)
- Testing
- QLV based implant strategy, Standard of care implant strategy
- Where
- 32 sites in United States
- Volunteers
- 248 people
- Sponsor
- Abbott Medical Devices
Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy
Ranolazine Implantable Cardioverter-Defibrillator Trial
The purpose of the study is to see how effective a drug called ranolazine is in reducing the risk of ventricular arrhythmia and death in people with implantable cardioverter-defibrillators (ICDs).
- Conditions
- Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy, Heart Failure
- Trial name
- RAID (NCT01215253)
- Testing
- Ranolazine
- Where
- 90 sites in United States, Canada
- Volunteers
- 1,012 people
- Sponsor
- University of Rochester
Non-ischemic Dilated Cardiomyopathy
PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)
The technique of transplanting progenitor cells into a region of damaged myocardium, termed cellular cardiomyoplasty1, is a potentially new therapeutic modality designed to replace or repair necrotic, scarred, or dysfunctional…
- Trial name
- PoseidonDCM (NCT01392625)
- Testing
- Autologous hMSCs, Allogeneic hMSCs
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Joshua M Hare
ISCHEMIC CARDIOMYOPATHY
Efficacy of EVP 1001-1 (SeeMore) in the Assessment of Myocardial Viability in Patients With Cardiovascular Disease
The investigator hopes to introduce a novel MRI contrast agent with SeeMore ™ that directly defines viable myocardium. Identifying viable myocardium non-invasively using cardiac MRI is still a moving target and a question we plan…
- Trial name
- NCT01989195
- Testing
- 'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Stanford University
Ischemic Cardiomyopathy
Autologous Stem Cells for Cardiac Angiogenesis (FOCUS HF)
This is a phase 1, single-blind trial to evaluate using autologous bone marrow mononuclear stem cells in ischemic cardiomyopathy patients.
- Trial name
- NCT00203203
- Testing
- Intramyocardial Injection of stem cells via NOGA Mapping, Control, then Stem Cell Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Texas Heart Institute
Dilated Cardiomyopathy, Ischemic Cardiomyopathy
Optimized Biventricular Pacing Allograft Recipients
This study tests optimization of biventricular pacing (BiVP) in patients with dilated cardiomyopathy (DCM) or ischemic cardiomyopathy (ICM) during cardiac transplantation in patients with advanced cardiac failure.
- Trial name
- BiBET (NCT01290822)
- Testing
- BiVP, AAI Pacing
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Henry M. Spotnitz
Chronic Ischemic Heart Disease, Left Ventricular Dysfunction
Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)
Coronary artery disease (CAD) is a common disorder that can lead to heart failure. Not all people with CAD are eligible for today's standard treatments.
- Conditions
- Chronic Ischemic Heart Disease, Left Ventricular Dysfunction, Angina, Ischemic Cardiomyopathy
- Trial name
- NCT00824005
- Testing
- Adult stem cells
- Where
- 5 sites in United States
- Volunteers
- 92 people
- Sponsor
- The University of Texas Health Science Center, Houston
Non-ischemic Cardiomyopathy, Systolic Heart Failure (NYHA II-III)
Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy
Non-ischemic cardiomyopathy and heart failure are highly influenced by the presence of systemic inflammation. Doxycycline is a FDA-approved drug to treat bacterial infections which also shows powerful anti-inflammatory effects.
- Trial name
- DOXY-HF (NCT01935622)
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Virginia Commonwealth University